Metabolic model predictions enable targeted microbiome manipulation through precision prebiotics

The microbiome is increasingly receiving attention as an important modulator of host health and disease. However, while numerous mechanisms through which the microbiome influences its host have been identified, there is still a lack of approaches that allow to specifically modulate the abundance of individual microbes or microbial functions of interest. Moreover, current approaches for microbiome manipulation such as fecal transfers often entail a non-specific transfer of entire microbial communities with potentially unwanted side effects. To overcome this limitation, we here propose the concept of precision prebiotics that specifically modulate the abundance of a microbiome member species of interest. In a first step, we show that defining precision prebiotics by compounds that are only taken up by the target species but no other species in a community is usually not possible due to overlapping metabolic niches. Subsequently, we present a metabolic modeling network framework that allows us to define precision prebiotics for a two-member C. elegans microbiome model community comprising the immune-protective Pseudomonas lurida MYb11 and the persistent colonizer Ochrobactrum vermis MYb71. Thus, we predicted compounds that specifically boost the abundance of the host-beneficial MYb11, four of which were experimentally validated in vitro (L-serine, L-threonine, D-mannitol, and γ-aminobutyric acid). L-serine was further assessed in vivo, leading to an increase in MYb11 abundance also in the worm host. Overall, our findings demonstrate that constraint-based metabolic modeling is an effective tool for the design of precision prebiotics as an important cornerstone for future microbiome-targeted therapies.

[1]  Juewon Kim,et al.  L-threonine promotes healthspan by expediting ferritin-dependent ferroptosis inhibition in C. elegans , 2022, Nature Communications.

[2]  Ahmad S. Khalil,et al.  Enhancing nutritional niche and host defenses by modifying the gut microbiome , 2022, Molecular systems biology.

[3]  P. Baloni,et al.  Constraint-Based Reconstruction and Analyses of Metabolic Models: Open-Source Python Tools and Applications to Cancer , 2022, Frontiers in Oncology.

[4]  Dongya Zhang,et al.  Microbiota in health and diseases , 2022, Signal Transduction and Targeted Therapy.

[5]  I. Thiele,et al.  Microbiome Modelling Toolbox 2.0: efficient, tractable modelling of microbiome communities , 2022, Bioinform..

[6]  E. Pamer,et al.  Microbiome-based therapeutics , 2022, Nature Reviews Microbiology.

[7]  R. Greiner,et al.  HMDB 5.0: the Human Metabolome Database for 2022 , 2021, Nucleic Acids Res..

[8]  Yishan Lu,et al.  Prevalence of virulence genes and antibiotic susceptibility of Bacillus used in commercial aquaculture probiotics in China , 2021 .

[9]  J. Ayroles,et al.  The microbiome extends host evolutionary potential , 2021, Nature Communications.

[10]  S. Mitragotri,et al.  The evolution of commercial drug delivery technologies , 2021, Nature Biomedical Engineering.

[11]  M. Félix,et al.  Natural genetic variation drives microbiome selection in the Caenorhabditis elegans gut , 2021, Current Biology.

[12]  Seon-Young Park,et al.  Fecal Microbiota Transplantation: Is It Safe? , 2021, Clinical endoscopy.

[13]  Silvio Waschina,et al.  Defining the nutritional input for genome-scale metabolic models: A roadmap , 2020, PloS one.

[14]  O. Kolodny,et al.  Microbiome-mediated plasticity directs host evolution along several distinct time scales , 2020, Philosophical Transactions of the Royal Society B.

[15]  H. Tilg,et al.  Microbial butyrate synthesis indicates therapeutic efficacy of azathioprine in IBD patients. , 2020, Journal of Crohn's & colitis.

[16]  Kinam Park,et al.  Advanced drug delivery 2020 and beyond: Perspectives on the future. , 2020, Advanced drug delivery reviews.

[17]  Ronan M. T. Fleming,et al.  Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions , 2020, BMC Biology.

[18]  D. Shawcross,et al.  Regulation, risk and safety of Faecal Microbiota Transplant , 2020, Infection Prevention in Practice.

[19]  L. Moles,et al.  The Impact of Diet on Microbiota Evolution and Human Health. Is Diet an Adequate Tool for Microbiota Modulation? , 2020, Nutrients.

[20]  N. Lewis,et al.  Dietary serine-microbiota interaction enhances chemotherapeutic toxicity without altering drug conversion , 2020, Nature Communications.

[21]  E. Elinav,et al.  Interaction between microbiota and immunity in health and disease , 2020, Cell Research.

[22]  Jingyuan Fu,et al.  Interaction between drugs and the gut microbiome , 2020, Gut.

[23]  B. Singh,et al.  Microbiome-Mediated Stress Resistance in Plants. , 2020, Trends in plant science.

[24]  M. Ribolsi,et al.  Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults , 2020, Nutrients.

[25]  C. Kaleta,et al.  gapseq: informed prediction of bacterial metabolic pathways and reconstruction of accurate metabolic models , 2020, Genome Biology.

[26]  J. Ugalde,et al.  Bacterially produced metabolites protect C. elegans neurons from degeneration , 2020, PLoS biology.

[27]  H. Schulenburg,et al.  Community assembly of the native C. elegans microbiome is influenced by time, substrate, and individual bacterial taxa. , 2020, Environmental microbiology.

[28]  E. Quigley,et al.  Recent advances in modulating the microbiome , 2020, F1000Research.

[29]  E. Im,et al.  Advances in colon-targeted nano-drug delivery systems: challenges and solutions , 2020, Archives of Pharmacal Research.

[30]  Kohske Takahashi,et al.  Welcome to the Tidyverse , 2019, J. Open Source Softw..

[31]  J. Raes,et al.  Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients with Inflammatory Bowel Diseases. , 2019, Gastroenterology.

[32]  A. Hirayama,et al.  Dietary L-serine confers a competitive fitness advantage to Enterobacteriaceae in the inflamed gut , 2019, Nature Microbiology.

[33]  C. Kaleta,et al.  The functional repertoire contained within the native microbiota of the model nematode Caenorhabditis elegans , 2019, The ISME Journal.

[34]  K. Bryson,et al.  Host-Microbe-Drug-Nutrient Screen Identifies Bacterial Effectors of Metformin Therapy , 2019, Cell.

[35]  Shu-jun Cao,et al.  Nanoparticles: Oral Delivery for Protein and Peptide Drugs , 2019, AAPS PharmSciTech.

[36]  B. Braeckman,et al.  The nutritional requirements of Caenorhabditis elegans , 2019, Genes & Nutrition.

[37]  B. Griffin,et al.  Gut Reactions: Breaking Down Xenobiotic–Microbiome Interactions , 2019, Pharmacological Reviews.

[38]  H. Bode,et al.  Natural C. elegans Microbiota Protects against Infection via Production of a Cyclic Lipopeptide of the Viscosin Group , 2019, Current Biology.

[39]  Y. Ghasemi,et al.  Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications , 2019, Foods.

[40]  S. Lynch,et al.  The gut microbiome: Relationships with disease and opportunities for therapy , 2018, The Journal of experimental medicine.

[41]  R. Parthasarathy,et al.  Modernized Tools for Streamlined Genetic Manipulation and Comparative Study of Wild and Diverse Proteobacterial Lineages , 2018, mBio.

[42]  Laurel A. Doherty,et al.  Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota , 2018, Front. Microbiol..

[43]  C. Pieterse,et al.  A Comparative Review on Microbiota Manipulation: Lessons From Fish, Plants, Livestock, and Human Research , 2018, Front. Nutr..

[44]  Arwen W. Gao,et al.  Glycine promotes longevity in Caenorhabditis elegans in a methionine cycle-dependent fashion , 2018, bioRxiv.

[45]  Hui Ling Lee,et al.  Targeted Approaches for In Situ Gut Microbiome Manipulation , 2018, Genes.

[46]  M. Platzer,et al.  Impairing L-Threonine Catabolism Promotes Healthspan through Methylglyoxal-Mediated Proteohormesis. , 2018, Cell metabolism.

[47]  D. Machado,et al.  Fast automated reconstruction of genome-scale metabolic models for microbial species and communities , 2018, bioRxiv.

[48]  J. Dwyer,et al.  Dietary Supplements: Regulatory Challenges and Research Resources , 2018, Nutrients.

[49]  S. Gorb,et al.  Targeted Microbiome Intervention by Microencapsulated Delayed-Release Niacin Beneficially Affects Insulin Sensitivity in Humans , 2017, Diabetes Care.

[50]  Johannes Zimmermann,et al.  BacArena: Individual-based metabolic modeling of heterogeneous microbes in complex communities , 2017, PLoS Comput. Biol..

[51]  I. Thiele,et al.  Gut microbiota functions: metabolism of nutrients and other food components , 2017, European Journal of Nutrition.

[52]  Ronan M. T. Fleming,et al.  Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota , 2016, Nature Biotechnology.

[53]  Bas Teusink,et al.  Constraint-based stoichiometric modelling from single organisms to microbial communities , 2016, Journal of The Royal Society Interface.

[54]  Benjamin M Hillmann,et al.  Stable Engraftment of Bifidobacterium longum AH1206 in the Human Gut Depends on Individualized Features of the Resident Microbiome. , 2016, Cell host & microbe.

[55]  D. Archana,et al.  Colon targeted drug delivery systems: A review on primary and novel approaches , 2016 .

[56]  P. Rosenstiel,et al.  The native microbiome of the nematode Caenorhabditis elegans: gateway to a new host-microbiome model , 2016, BMC Biology.

[57]  Zachary A. King,et al.  Constraint-based models predict metabolic and associated cellular functions , 2014, Nature Reviews Genetics.

[58]  Amit G Singal,et al.  A Primer on Effectiveness and Efficacy Trials , 2014, Clinical and Translational Gastroenterology.

[59]  Martin J. Lercher,et al.  sybil – Efficient constraint-based modelling in R , 2013, BMC Systems Biology.

[60]  A. Hou,et al.  Host-Microbe Interactions in Caenorhabditis elegans , 2013, ISRN microbiology.

[61]  Gabriel Núñez,et al.  Control of pathogens and pathobionts by the gut microbiota , 2013, Nature Immunology.

[62]  Ronan M. T. Fleming,et al.  Systems-level characterization of a host-microbe metabolic symbiosis in the mammalian gut , 2013, Gut microbes.

[63]  Cedric E. Ginestet ggplot2: Elegant Graphics for Data Analysis , 2011 .

[64]  D. Schomburg,et al.  How Pseudomonas aeruginosa adapts to various environments: a metabolomic approach. , 2010, Environmental microbiology.

[65]  Jeffrey D Orth,et al.  What is flux balance analysis? , 2010, Nature Biotechnology.

[66]  Theresa Stiernagle Maintenance of C. elegans. , 2006, WormBook : the online review of C. elegans biology.

[67]  Michael Krawczak,et al.  PopGen: Population-Based Recruitment of Patients and Controls for the Analysis of Complex Genotype-Phenotype Relationships , 2006, Public Health Genomics.

[68]  T. Leisinger,et al.  Regulation of proline catabolism in Pseudomonas aeruginosa PAO , 1982, Archives of Microbiology.

[69]  Richard Soltero,et al.  The oral delivery of protein and peptide drugs , 2003 .

[70]  F. Neidhardt,et al.  Formation and Operation of the Histidine-degrading Pathway in Pseudomonas aeruginosa , 1967, Journal of bacteriology.

[71]  M. Doudoroff,et al.  The aerobic pseudomonads: a taxonomic study. , 1966, Journal of general microbiology.

[72]  F. Wilcoxon Individual Comparisons by Ranking Methods , 1945 .